Sanjay Srivastava
Critical Care Medicine · Ashtabula, OHNPI 1932364940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by GSK at 24.1% of the total. 2025 is the largest year on record at $1,530, more than ten times the $67 reported in 2019.
Across 112 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$531
- AstraZeneca$297
- Sanofi$284
- Regeneron Healthcare Solutions, Inc.$201
- Amgen$155
- Mylan Specialty L.p.$143
- plus $588 from 14 others
What the payments were for
- Food & beverage$2,08395%
- Education$1175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 31 | $531 |
| AstraZeneca | 15 | $297 |
| Sanofi | 14 | $284 |
| Regeneron Healthcare Solutions, Inc. | 8 | $201 |
| Amgen | 10 | $155 |
| Mylan Specialty L.p. | 6 | $143 |
| Abbott | 6 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Lilly USA, LLC | 3 | $66 |
| Viatris Specialty LLC | 3 | $57 |
| Insmed, Inc. | 3 | $49 |
| Koya Medical, Inc. | 2 | $41 |
| Genentech USA, Inc. | 2 | $36 |
| Cardiovascular Systems Inc. | 2 | $26 |
| Convatec Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Organogenesis Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Saluda Medical Americas, Inc. | 1 | $15 |
How this compares
$2,200 in reported general payments places this provider in the 85th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 873 | $674,840 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 113 | $74,991 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $43,404 |
| Spiriva RespimatTiotropium Bromide | 62 | $40,936 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 57 | $39,383 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $28,803 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 646 | $19,292 |
| DuleraMometasone/Formoterol | 46 | $16,673 |
| EliquisApixaban | 19 | $15,057 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $12,363 |
| Ventolin HfaAlbuterol Sulfate | 137 | $9,982 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $9,836 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $8,162 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 62 | $6,060 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $531 | $750,8161,030 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $297 | $95,517186 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $15 | $80,319119 claims |
| PfizerEliquis | $17 | $15,05719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Ashtabula
- Neal ChaissonCleveland$428K
- Robert SchilzCleveland$356K
- Nicholas PastisColumbus$145K
- Michael EssandohColumbus$135K
- Chiedozie UdehCleveland$24K
- Kari GorderColumbus$20K
- Elliott CrouserColumbus$16K
- Sadia BenzaquenCincinnati$15K
- Lawrence GoldsteinBoardman$12K
- Georges YacoubTroy$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.